AXELERA-AI
European artificial intelligence (AI) startup Axelera AI announced today its Metis AI Platform, encompassing the MetisTM AI Processing Unit (AIPU) chip and the VoyagerTM SDK software stack – available as cards, boards, and vision systems – to accelerate computer vision processing at the edge.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221213005651/en/
About the Axelera AI Metis AI platform. (Graphic: Business Wire)
The Metis AI Platform redefines affordability for Edge AI solutions without compromising on performance and is the first product in the market to offer hundreds of TeraOPS (TOPs) compute performance at an edge price-point. The products will be available in different form factors: an Edge M.2 acceleration card, offering up to 214 TOPs priced from $149, corresponding to only $0.70 per TOPs, as well as a PCIe card delivering up to 856 TOPs, powered by four Metis AIPUs. Separately, Axelera AI is working with partners to develop system ready solutions.
Axelera’s Metis AIPU delivers an unprecedented peak performance of 214 TOPs with an energy efficiency of 15 TOPs/W at INT8, thanks to a novel Digital In-Memory Computing (D-IMC) engine. FP32 iso-accuracy is achieved without the need to retrain the neural network models.
The software stack, Voyager SDK, includes an integrated compiler, a runtime stack and powerful optimization tools that enable customers to import their own models delivering class-leading performance on the Metis AI platform. Application templates speed up development, with customers able to choose from Axelera’s carefully curated Model Zoo.
Axelera AI opens the Early Access Program a unique collaboration opportunity for leading companies to co-design real-world Edge AI solutions based on the Metis AI platform. The Metis AI platform will be available for selected customers in early 2023. For more information, visit www.axelera.ai.
About Axelera AI
Axelera AI is designing the world’s most powerful and advanced solutions for AI at the edge. Its game-changing MetisTM AI platform – a holistic hardware and software solution for AI interference at the edge – enables computer vision applications to become more accessible, powerful and user friendly than ever before. Headquartered in the AI Innovation Center of the High Tech Campus in Eindhoven, Axelera AI has R&D offices in Belgium, Switzerland, Italy and the UK, with 100 employees in 11 countries. Its team of experts in AI software and hardware hail from top AI firms and Fortune 500 companies. Visit the Axelera AI website for more information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005651/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DATA appoints CEO of newly established AI Company NTT DATA AIVista, Inc.9.12.2025 14:00:00 CET | Press release
Dr. Bratin Saha joins NTT DATA AIVista, Inc., bringing extensive experience in AI, infrastructure, platforms and solutions NTT DATA AIVista, Inc. established in Silicon Valley to help NTT operating companies accelerate the launch and scaling of AI native businesses NTT DATA, a global leader in AI, digital business and technology services, today announced the appointment of Dr. Bratin Saha as CEO of the newly established AI Company, NTT DATA AIVista, Inc., effective Dec 1, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209189202/en/ Dr. Bratin Saha, newly appointed CEO of NTT DATA AIVista, Inc. Saha brings deep expertise in AI, infrastructure, platforms and solutions; scaling new businesses and significant ecosystem relationships. Prior to joining NTT DATA, he held executive positions at NVIDIA, Amazon Web Services (AWS) and most recently DigitalOcean. At NVIDIA, Saha served as Vice President of Software Infrastructu
Aqemia to Attend the 44th Annual J.P. Morgan Healthcare Conference 20269.12.2025 14:00:00 CET | Press release
Aqemia, a drug invention company combining generative AI and quantum-inspired physics, announces it will attend and hold 1x1 meetings at the 44th Annual J.P. Morgan Healthcare Conference, taking place at The Westin St. Francis in San Francisco from January 12 to 15, 2026. Aqemia will be represented by Maximilien Levesque, CEO and co-founder, Emmanuelle Martiano, COO and co-founder, and Théa Vu-Bignand, VP Finance. Powered by QEMI, its proprietary physics-based generative AI engine for therapeutic molecule invention, Aqemia designs novel drug candidates in a repeatable, efficient, and scalable way. The company focuses on advancing its internal preclinical pipeline while establishing partnerships that validate its platform and scientific differentiation, with the ambition to accelerate the delivery of new therapies in areas of high unmet medical need. About Aqemia Aqemia is a drug invention company dedicated to creating novel molecules to address unmet medical needs. Its proprietary QEMI
Avia Expands to Europe with New German Subsidiary9.12.2025 14:00:00 CET | Press release
AviaGames, a leading global mobile skill-based gaming platform, today announced the establishment of a new subsidiary in Germany. Games industry veteran Michelle Zou has been appointed to head the new entity, overseeing market expansion and investment initiatives across Europe. This move marks a significant milestone in AviaGames’ global growth strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209920028/en/ Games industry veteran Michelle Zou has been appointed to head the AviaGames German subsidiary, overseeing market expansion and investment initiatives across Europe. AviaGames has rapidly emerged as one of the most prominent interactive entertainment companies worldwide, with a global user base of tens of millions of players across North America, and Europe, spanning North America and beyond. The company is especially recognized for its popularity among female players and for delivering high-quality, skill-based
ExaGrid Wins 3 New Industry Awards at the MSP Channel Awards9.12.2025 14:00:00 CET | Press release
Awards highlight ExaGrid’s achievements in the MSP sector ExaGrid®, the industry’s only Tiered Backup Storage solution with AI-Powered Retention Time-Lock (RTL) that includes a non-network-facing tier (tiered air gap), Auto Detect & Guard, delayed deletes and immutability for ransomware recovery, today announced that the company was honored with three awards during the 1st annual MSP Channel Awards ceremony, held in London on December 3, 2025, including: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209577454/en/ Photo courtesy of MSP Channel Awards. Backup & DR Innovation of the Year Storage Hardware Innovation of the Year Storage Vendor of the Year Many Managed Service Providers (MSPs) use ExaGrid Tiered Backup Storage to offer their customers Backup as a Service (BaaS), Disaster Recovery as a Service (DRaaS), and IT Data Center Outsourcing. In 2025, ExaGrid released new features that help MSPs track their customers’ d
SciencePower Collaborates to Advance Research on Postbiotics in Breast Cancer Biology9.12.2025 13:00:00 CET | Press release
SciencePower, a next-generation postbiotic platform company, today announced that it has entered into a license agreement with Mayo Clinic. The agreement enables collaborative research led by Mayo Clinic investigators to explore the potential of SciencePower’s proprietary postbiotic compositions in breast cancer biology. The collaboration will focus on understanding how specific microbiome-derived compositions influence immune and cellular pathways relevant to breast cancer. Early preclinical findings are currently planned to be presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2025. “This milestone marks an important step in validating our technology through rigorous scientific collaboration,” said Robin Albin, SciencePower Co-Founder, Marketing & Communications. “We are honored to work with Mayo Clinic researchers to deepen the understanding of postbiotics and their potential role in advancing human health.” Mayo Clinic has a financial interest in SciencePower
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom